NCT06782542
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06782542 |
| Title | Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy (OLUVENAZA) |
| Acronym | OLUVENAZA |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Justin Watts, MD |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
CKB BOOST